BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdel-Rahman O, Abdel-Wahab M, Shaker M, Abdel-Wahab S, Elbassiony M, Ellithy M. Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. Med Oncol 2013;30:655. [PMID: 23824645 DOI: 10.1007/s12032-013-0655-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis. Crit Rev Oncol Hematol 2014;92:194-207. [PMID: 25028151 DOI: 10.1016/j.critrevonc.2014.06.003] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
2 Brandi G, Venturi M, De Lorenzo S, Garuti F, Frega G, Palloni A, Garajovà I, Abbati F, Saccoccio G, Golfieri R, Pantaleo MA, Barbera MA. Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases. Cancer Commun (Lond) 2018;38:41. [PMID: 29941039 DOI: 10.1186/s40880-018-0312-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A, Granito A, Tovoli F, De Lorenzo S, Inghilesi AL, Foschi FG, Bernardi M, Marra F, Sacco R, Di Costanzo GG. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol 2018;144:403-14. [PMID: 29249005 DOI: 10.1007/s00432-017-2556-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
4 Fouad M, Abdel-Rahman O. Combination of transarterial chemoembolisation (TACE) plus antivirals for the management of hepatitis B-related hepatocellular carcinoma: A systematic review of the literature. Arab J Gastroenterol 2015;16:40-5. [PMID: 25910573 DOI: 10.1016/j.ajg.2015.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Li JQ, Wu X, Gan L, Yang XL, Miao ZH. Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells. Acta Pharmacol Sin 2017;38:1642-54. [PMID: 28713155 DOI: 10.1038/aps.2017.79] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
6 Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. J Egypt Natl Canc Inst. 2013;25:165-171. [PMID: 24207088 DOI: 10.1016/j.jnci.2013.08.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
7 Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Future Oncol 2014;10:1981-92. [PMID: 25386814 DOI: 10.2217/fon.14.42] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
8 McNamara MG, Slagter AE, Nuttall C, Frizziero M, Pihlak R, Lamarca A, Tariq N, Valle JW, Hubner RA, Knox JJ, Amir E. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer 2018;105:1-9. [PMID: 30384012 DOI: 10.1016/j.ejca.2018.09.031] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
9 Huang CC, Hwang JM, Tsai JH, Chen JH, Lin H, Lin GJ, Yang HL, Liu JY, Yang CY, Ye JC. Aqueous Ocimum gratissimum extract induces cell apoptosis in human hepatocellular carcinoma cells. Int J Med Sci 2020;17:338-46. [PMID: 32132869 DOI: 10.7150/ijms.39436] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Abouelezz K, Khanapara D, Batiha GE, Ahmed EA, Hetta HF. Cytotoxic Chemotherapy as an Alternative for Systemic Treatment of Advanced Hepatocellular Carcinoma in Developing Countries. Cancer Manag Res 2020;12:12239-48. [PMID: 33273860 DOI: 10.2147/CMAR.S280631] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Eatrides J, Wang E, Kothari N, Kim R. Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma. Cancer Control. 2017;24:1073274817729243. [PMID: 28975834 DOI: 10.1177/1073274817729243] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
12 Khedr GAE, Elzawawy SF, Gowil AG, Elyamany AS, Eshafei M. Metronomic capecitabine versus doxorubicin in advanced hepatocellular carcinoma. Korean J Clin Oncol 2016;12:32-40. [DOI: 10.14216/kjco.16006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group Of Japan. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. Oncotarget 2016;7:64400-9. [PMID: 27462865 DOI: 10.18632/oncotarget.10794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Abdel-rahman O, Fouad M. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 2015;93:127-35. [DOI: 10.1016/j.critrevonc.2014.07.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
15 Abdel-Rahman O, ElHalawani H. Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns. Expert Opin Drug Saf 2014;13:1443-67. [PMID: 25244502 DOI: 10.1517/14740338.2014.955848] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 He L, Zhou X, Qu C, Tang Y, Zhang Q, Hong J. Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients. Med Oncol. 2013;30:707. [PMID: 23996242 DOI: 10.1007/s12032-013-0707-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
17 Abdel-Rahman O, Fouad M. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature. J Cancer Res Clin Oncol. 2015;141:295-305. [PMID: 24990591 DOI: 10.1007/s00432-014-1757-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
18 Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit Rev Oncol Hematol. 2014;91:1-8. [PMID: 24457121 DOI: 10.1016/j.critrevonc.2013.12.013] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
19 Nguyen K, Jack K, Sun W. Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases 2015;4:E1. [PMID: 28933381 DOI: 10.3390/diseases4010001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
20 Hanafy AS. Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience. Springerplus 2016;5:1675. [PMID: 27733977 DOI: 10.1186/s40064-016-3376-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol. 2017;8:256-265. [PMID: 28480065 DOI: 10.21037/jgo.2016.09.07] [Cited by in Crossref: 90] [Cited by in F6Publishing: 94] [Article Influence: 18.0] [Reference Citation Analysis]
22 Abdel-rahman O, Fouad M. Risk of fatigue and hepatic and metabolic toxicities in patients with solid tumors treated with everolimus: a meta-analysis. Future Oncology 2015;11:79-90. [DOI: 10.2217/fon.14.136] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
23 Abdel-Rahman O, Fouad M. Does the use of lapatinib increase the risk of fatigue and hepatic toxicities in patients with solid tumors? A critical literature review and meta-analysis. Expert Opin Drug Saf 2014;13:999-1008. [PMID: 24930544 DOI: 10.1517/14740338.2014.921679] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
24 Abdel-rahman O. Revisiting Oxaliplatin-based Regimens for Advanced Hepatocellular Carcinoma. Curr Oncol Rep 2014;16. [DOI: 10.1007/s11912-014-0394-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
25 Ronnebaum S, Aly A, Patel D, Benavente F, Rueda JD. Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. Hepat Oncol 2022;9:HEP41. [PMID: 34765109 DOI: 10.2217/hep-2021-0003] [Reference Citation Analysis]
26 Pelizzaro F, Sammarco A, Dadduzio V, Pastorelli D, Giovanis P, Soldà C, Rizzato MD, Lombardi G, Lonardi S, Peserico G, Imondi A, Sartori A, Maddalo G, Farinati F. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. Digestive and Liver Disease 2019;51:1713-9. [DOI: 10.1016/j.dld.2019.06.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
27 Abdel-rahman O, Fouad M. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. Expert Review of Anticancer Therapy 2014;14:1063-73. [DOI: 10.1586/14737140.2014.929501] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
28 Medavaram S, Zhang Y. Emerging therapies in advanced hepatocellular carcinoma. Exp Hematol Oncol. 2018;7:17. [PMID: 30087805 DOI: 10.1186/s40164-018-0109-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 11.0] [Reference Citation Analysis]
29 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
30 Kohorst MA, Warad DM, Matsumoto JM, Heimbach JK, El-Youssef M, Arndt CAS, Rodriguez V, Nageswara Rao AA. Management of pediatric hepatocellular carcinoma: A multimodal approach. Pediatr Transplant 2017;21. [PMID: 28631359 DOI: 10.1111/petr.13007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
31 Peng S, Zhao Y, Xu F, Jia C, Xu Y, Dai C. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma. PLoS One. 2014;9:e112530. [PMID: 25460347 DOI: 10.1371/journal.pone.0112530] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
32 Lu LC, Chang CJ, Hsu CH. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. J Hepatocell Carcinoma. 2019;6:71-84. [PMID: 31123667 DOI: 10.2147/jhc.s159693] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]